Jeremy Paull
Chief Scientific & Regulatory Officer Starpharma Ltd.
Seminars
Tuesday 11th November 2025
Engineering Targeted Radiopharmaceuticals: DEP Dendrimer Nanoparticles for Optimised Biodistribution and Efficacy
11:00 am
- DEP dendrimers can be precisely engineered to achieve targeted pharmacokinetic and biodistribution objectives, illustrated by contrasting dendrimer profiles.
- Methods for predicting human radiation doses from preclinical data to validate dendrimer design criteria are being combined with the strategic use of predicted human dosimetry estimates to guide the selection of lead dendrimer candidates.
- DEP dendrimers represent a versatile solution to overcome biodistribution challenges, and enhance therapeutic efficacy.
